ISRCTN66874446 https://doi.org/10.1186/ISRCTN66874446

UK Trial of Radioiodine Intervention in Subclinical Hyperthyroidism

Submission date	Recruitment status	[X] Prospectively registered
16/12/2005	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
08/08/2006	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
13/11/2017	Nutritional, Metabolic, Endocrine	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Simon Pearce

Contact details
School of Clinical Medical Sciences
University of Newcastle
Newcastle upon Tyne
United Kingdom
NE2 4HH
-
s.h.s.pearce@ncl.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
G0500783

Study information

Scientific Title
UK Trial of Radioiodine Intervention in Subclinical Hyperthyroidism

Acronym
TRISH

Study objectives
Radioiodine treatment for sustained subclinical hyperthyroidism will not reduce circulatory endpoints in the elderly.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approval gained from the Newcastle and North Tyneside Research Ethics Committee (reference number: 06/Q0905/112).

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Subclinical hyperthyroidism

Interventions
Radioiodine treatment versus usual care.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Radioiodine

Primary outcome measure
Composite circulatory mortality

Secondary outcome measures
1. All cause mortality
2. Atrial fibrillation
3. Progression to overt
hyperthyroidism
4. Hip and vertebral fractures
5. MMTS

Overall study start date
01/10/2006

Completion date
30/09/2015

Eligibility

Key inclusion criteria
1. Over 65 years of age
2. Sustained subclinical hyperthyroidism (undetectable Thyroid Stimulating Hormome [TSH], normal free thyroid
hormones) for greater than three months

Participant type(s)
Patient

Age group
Senior

Sex
Both

Target number of participants
780

Key exclusion criteria
1. Patient currently has or has ever had Atrial Fibrillation (AF)
2. Certain drug usage
3. Pituitary, severe renal or hepatic disease
4. Unstable coronary disease

Date of first enrolment
01/10/2006

Date of final enrolment
30/09/2015

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
School of Clinical Medical Sciences
Newcastle upon Tyne
United Kingdom
NE2 4HH

Sponsor information

Organisation
Newcastle upon Tyne Hospitals NHS Trust (UK)

Sponsor details
Research and Development Department
Clinical Research Facility
Leazes Wing, 4th Floor
Royal Victoria Infirmary
Newcastle upon Tyne
England
United Kingdom
NE1 4LP

Sponsor type
Hospital/treatment centre

ROR
https://ror.org/05p40t847

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2008		Yes	No